Wednesday, October 14, 2026

Back to today

October 2026 Random Ramblings

October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI premiums for Oura and home builders.

From X

@StableBread

Fajasy on X

One AI data labeling contract could be worth multiples of the $500,586 of revenue Nubeva Technologies $NBVAF (TSXV: $NBVA) booked in FY2026. Its CEO said in a new interview that data labeling companies (firms that turn experts’ knowledge into training data for AI labs) have asked the company to help label malware, and that most of its engineering focus is now on training its own AI model to read malware binaries. Nubeva now has three ways to pay off, up from two: → Having AI write the decryptors for its key-capture software, Ransomware Reversal (NuRR), so Nubeva can grow again or attract a partner/buyer. → A partnership or sale following the approval of all four AI patents. → Selling binary analysis (labeling what malware programs do) to data labeling companies, which could also attract a partner/buyer. Moreover, a data labeling contract wouldn’t depend on NuRR’s sales or on AI writing its decryptors, so it could come before either of the other two routes. CEO Randy Chou gave no price, volume, or timeline for a contract. But if you were to extrapolate the $200-250/hour that Mercor, one of the largest data labeling companies, pays its security experts, one full-time contractor (~2,000 hours/year) would earn $400-500K/year, just about Nubeva’s FY2026 revenue of $500,586. That implies Nubeva could earn multiples of its revenue from a single data labeling contract if its engineers and model can do the work of several contractors. A contract worth three of Mercor’s full-time experts ($1.2-1.5M/year) would be 2.4-3.0x its FY2026 revenue.

LQDA: finer powder, higher doses

Liquidia’s Yutrepia sales reached $170.4 million in Q2 2026, while a patent ruling threatens its PH-ILD label but leaves PAH sales and a…

SRTA · long

Strata Critical Medical INC

Strata Critical Medical, SRTA, supplies organ-transport products tied to U.S. transplant growth.

Deep Dive: Inter & Co

Inter & Co, Brazil’s second-largest neobank, grew over 20% with controlled delinquencies and 15% book-value compounding while trading at…

You Understand Now, Why You Came This Way

Brazil’s October 25 runoff puts Bolsonaro’s likely victory at the center of a bullish regional-stock case; Golar LNG (GLNG) also reports…

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

X accounts we follow

Every account on this site, hand-picked.

88 accounts

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.